Immunovaccine appoints new audit chair
This article was originally published in Scrip
Immunovaccine Inc, a Canadian vaccine development company, has appointed James Hall to its Board of Directors. Mr Hall will serve as chair of the audit committee, bringing over 25 years' experience in finance and investment to the role. He currently serves as president and CEO of James Hall Advisors, and has held previous roles in both senior and board positions at Working Ventures Canadian Fund, Global Credit Pref Corp, and Adventus Intellectual Property Inc. Mr Hall will work with the board to progress Immunovaccine's DepoVax vaccine delivery technology into the clinic, as well as to build shareholder value. He has been granted 50,000 stock options, which have a term of five years, under Immunovaccine's stock option plan.